0 XP   0   0   0

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.










Financial Health of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.




Comparing to competitors in the industry




  Industry Rankings  


SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Buy, Hold or Sell?

Should you buy, hold or sell SUN PHARMA ADVANCED RESEARCH COMPANY LTD.?

I guess you are interested in SUN PHARMA ADVANCED RESEARCH COMPANY LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Let's start. I'm going to help you getting a better view of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is SUN PHARMA ADVANCED RESEARCH COMPANY LTD. even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is doing in the market. If the company is worth buying. The latest step is to find out how other investors value SUN PHARMA ADVANCED RESEARCH COMPANY LTD.. The closing price on 2022-12-05 was INR249.50 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

1.1. Profitability of SUN PHARMA ADVANCED RESEARCH COMPANY LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit SUN PHARMA ADVANCED RESEARCH COMPANY LTD. earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • A Net Profit Margin of -216.9% means that ₹-2.17 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is -216.9%. The company is making a huge loss. -2
  • The TTM is -249.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-216.9%TTM-249.2%+32.3%
TTM-249.2%YOY-197.8%-51.3%
TTM-249.2%5Y-232.1%-17.1%
5Y-232.1%10Y-232.1%0.0%
1.1.2. Return on Assets

Shows how efficient SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • -23.4% Return on Assets means that SUN PHARMA ADVANCED RESEARCH COMPANY LTD. generated ₹-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is -23.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.4%TTM-24.4%+1.0%
TTM-24.4%YOY-18.6%-5.7%
TTM-24.4%5Y-22.5%-1.9%
5Y-22.5%10Y-22.5%0.0%
1.1.3. Return on Equity

Shows how efficient SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • 0.0% Return on Equity means SUN PHARMA ADVANCED RESEARCH COMPANY LTD. generated ₹0.00 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-113.8%+113.8%
TTM-113.8%YOY-1,168.2%+1,054.5%
TTM-113.8%5Y-465.2%+351.5%
5Y-465.2%10Y-465.2%0.0%

1.2. Operating Efficiency of SUN PHARMA ADVANCED RESEARCH COMPANY LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is operating .

  • Measures how much profit SUN PHARMA ADVANCED RESEARCH COMPANY LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
1.2.2. Operating Ratio

Measures how efficient SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 4.12 means that the operating costs are ₹4.12 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 4.122. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.702. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.122TTM4.702-0.580
TTM4.702YOY4.182+0.520
TTM4.7025Y4.529+0.173
5Y4.52910Y4.5290.000

1.3. Liquidity of SUN PHARMA ADVANCED RESEARCH COMPANY LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 0.22 means the company has ₹0.22 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 0.223. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.319. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.223TTM0.319-0.096
TTM0.319YOY0.684-0.365
TTM0.3195Y0.441-0.122
5Y0.44110Y0.4410.000
1.3.2. Quick Ratio

Measures if SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • A Quick Ratio of 0.13 means the company can pay off ₹0.13 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 0.129. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.179. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.129TTM0.179-0.050
TTM0.179YOY0.248-0.068
TTM0.1795Y0.202-0.023
5Y0.20210Y0.2020.000

1.4. Solvency of SUN PHARMA ADVANCED RESEARCH COMPANY LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to industry mean.
  • A Debt to Asset Ratio of 1.41 means that SUN PHARMA ADVANCED RESEARCH COMPANY LTD. assets are financed with 140.6% credit (debt) and the remaining percentage (100% - 140.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 1.406. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.147. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.406TTM1.147+0.259
TTM1.147YOY0.984+0.163
TTM1.1475Y1.093+0.054
5Y1.09310Y1.0930.000
1.4.2. Debt to Equity Ratio

Measures if SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • A Debt to Equity ratio of 0.0% means that company has ₹0.00 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.985-3.985
TTM3.985YOY61.665-57.680
TTM3.9855Y23.212-19.227
5Y23.21210Y23.2120.000

2. Market Valuation of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings SUN PHARMA ADVANCED RESEARCH COMPANY LTD. generates.

  • Above 15 is considered overpriced but always compare SUN PHARMA ADVANCED RESEARCH COMPANY LTD. to the  industry mean.
  • A PE ratio of -88.44 means the investor is paying ₹-88.44 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The EOD is -100.431. Company is losing money. -2
  • The MRQ is -88.436. Company is losing money. -2
  • The TTM is -101.018. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-100.431MRQ-88.436-11.995
MRQ-88.436TTM-101.018+12.582
TTM-101.018YOY-141.353+40.336
TTM-101.0185Y-114.463+13.445
5Y-114.46310Y-114.4630.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of SUN PHARMA ADVANCED RESEARCH COMPANY LTD..

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The MRQ is -1,705.353. Very Bad. -2
  • The TTM is -567.323. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-1,705.353TTM-567.323-1,138.030
TTM-567.3235Y-567.3230.000
5Y-567.32310Y-567.3230.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of -50.97 means the investor is paying ₹-50.97 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of SUN PHARMA ADVANCED RESEARCH COMPANY LTD.:

  • The EOD is -57.882. Bad. Book ratio is negative. -2
  • The MRQ is -50.969. Bad. Book ratio is negative. -2
  • The TTM is 103.748. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD-57.882MRQ-50.969-6.913
MRQ-50.969TTM103.748-154.717
TTM103.748YOY1,651.319-1,547.572
TTM103.7485Y619.605-515.857
5Y619.60510Y619.6050.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---5.459-2.245-59%0.179-3147%-1.437-74%-1.437-74%
Book Value Growth---1.003-0.003-100%---0.003-100%-0.003-100%
Book Value Per Share---4.310-1.581-63%0.179-2506%-0.994-77%-0.994-77%
Book Value Per Share Growth---1.266-0.211-83%---0.211-83%-0.211-83%
Current Ratio--0.2230.319-30%0.684-67%0.441-49%0.441-49%
Debt To Asset Ratio--1.4061.147+23%0.984+43%1.093+29%1.093+29%
Debt To Equity Ratio---3.985-100%61.665-100%23.212-100%23.212-100%
Dividend Per Share----0%-0%-0%-0%
Eps---2.484-2.549+3%-2.093-16%-2.397-4%-2.397-4%
Eps Growth--0.052-0.074+242%---0.074+242%-0.074+242%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---2.169-2.492+15%-1.978-9%-2.321+7%-2.321+7%
Operating Margin----0%-0%-0%-0%
Operating Ratio--4.1224.702-12%4.182-1%4.529-9%4.529-9%
Pb Ratio-57.882-14%-50.969103.748-149%1651.319-103%619.605-108%619.605-108%
Pe Ratio-100.431-14%-88.436-101.018+14%-141.353+60%-114.463+29%-114.463+29%
Peg Ratio---1705.353-567.323-67%---567.323-67%-567.323-67%
Price Per Share249.500+12%219.700258.275-15%295.850-26%270.800-19%270.800-19%
Price To Total Gains Ratio-45.704-14%-40.246132.995-130%1651.319-102%639.103-106%639.103-106%
Profit Growth---98.733-98.893+0%---98.893+0%-98.893+0%
Quick Ratio--0.1290.179-28%0.248-48%0.202-36%0.202-36%
Return On Assets---0.234-0.244+4%-0.186-20%-0.225-4%-0.225-4%
Return On Equity----1.1380%-11.6820%-4.6520%-4.6520%
Revenue Growth--0.9900.988+0%--0.988+0%0.988+0%
Total Gains Per Share---5.459-2.245-59%0.179-3147%-1.437-74%-1.437-74%
Total Gains Per Share Growth---1.178-0.181-85%---0.181-85%-0.181-85%
Usd Book Value---14478960.000-5334712.300-63%575840.000-2614%-3364528.200-77%-3364528.200-77%
Usd Book Value Change Per Share---0.067-0.027-59%0.002-3147%-0.018-74%-0.018-74%
Usd Book Value Per Share---0.053-0.019-63%0.002-2506%-0.012-77%-0.012-77%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.030-0.031+3%-0.026-16%-0.029-4%-0.029-4%
Usd Price Per Share3.044+12%2.6803.151-15%3.609-26%3.304-19%3.304-19%
Usd Profit---8344800.000-8506169.400+2%-6727080.000-19%-7913139.600-5%-7913139.600-5%
Usd Revenue--3847880.0003463512.900+11%3400140.000+13%3442388.600+12%3442388.600+12%
Usd Total Gains Per Share---0.067-0.027-59%0.002-3147%-0.018-74%-0.018-74%
 EOD+3 -2MRQTTM+14 -16YOY+5 -185Y+10 -2010Y+10 -20

3.2. Fundamental Score

Let's check the fundamental score of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-100.431
Price to Book Ratio (EOD)Between0-1-57.882
Net Profit Margin (MRQ)Greater than0-2.169
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.129
Current Ratio (MRQ)Greater than10.223
Debt to Asset Ratio (MRQ)Less than11.406
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.234
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose253.250
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in INR. All numbers in thousands.

Summary
Total Assets2,923,700
Total Liabilities4,110,500
Total Stockholder Equity-1,186,800
 As reported
Total Liabilities 4,110,500
Total Stockholder Equity+ -1,186,800
Total Assets = 2,923,700

Assets

Total Assets2,923,700
Total Current Assets734,000
Long-term Assets734,000
Total Current Assets
Cash And Cash Equivalents 21,900
Short-term Investments 75,700
Net Receivables 348,300
Other Current Assets 285,500
Total Current Assets  (as reported)734,000
Total Current Assets  (calculated)731,400
+/- 2,600
Long-term Assets
Intangible Assets 230,600
Long-term Assets Other 3,500
Long-term Assets  (as reported)2,189,700
Long-term Assets  (calculated)234,100
+/- 1,955,600

Liabilities & Shareholders' Equity

Total Current Liabilities3,289,300
Long-term Liabilities821,200
Total Stockholder Equity-1,186,800
Total Current Liabilities
Short Long Term Debt 1,825,200
Accounts payable 1,209,400
Other Current Liabilities 103,300
Total Current Liabilities  (as reported)3,289,300
Total Current Liabilities  (calculated)3,137,900
+/- 151,400
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt101,600
Long-term Liabilities Other 668,400
Long-term Liabilities  (as reported)821,200
Long-term Liabilities  (calculated)770,000
+/- 51,200
Total Stockholder Equity
Total Stockholder Equity (as reported)-1,186,800
Total Stockholder Equity (calculated)0
+/- 1,186,800
Other
Capital Stock271,900
Common Stock Shares Outstanding 275,329
Net Debt 1,803,300
Net Invested Capital 638,400
Net Working Capital -2,555,300



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-09-302022-03-312021-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
0
0
0
0
2,957,800
2,800,828
2,923,700
2,923,7002,800,8282,957,8000000
   > Total Current Assets 
1,094,000
0
671,880
0
1,387,000
711,523
734,000
734,000711,5231,387,0000671,88001,094,000
       Cash And Cash Equivalents 
0
0
0
0
582,500
12,242
21,900
21,90012,242582,5000000
       Short-term Investments 
0
0
0
0
265,000
116,649
75,700
75,700116,649265,0000000
       Net Receivables 
208,200
0
168,186
0
237,400
277,361
348,300
348,300277,361237,4000168,1860208,200
       Other Current Assets 
322,700
0
361,862
0
301,100
273,400
285,500
285,500273,400301,1000361,8620322,700
   > Long-term Assets 
0
0
0
0
1,570,800
2,089,305
2,189,700
2,189,7002,089,3051,570,8000000
       Property Plant Equipment 
973,700
0
1,065,584
0
0
0
0
00001,065,5840973,700
       Intangible Assets 
0
0
0
0
24,400
231,157
230,600
230,600231,15724,4000000
       Long-term Assets Other 
0
0
0
0
4,000
6,000
3,500
3,5006,0004,0000000
> Total Liabilities 
0
0
0
0
2,910,600
2,488,571
4,110,500
4,110,5002,488,5712,910,6000000
   > Total Current Liabilities 
1,197,300
0
2,353,554
0
2,027,800
1,714,289
3,289,300
3,289,3001,714,2892,027,80002,353,55401,197,300
       Short Long Term Debt 
0
0
0
0
1,125,000
750,000
1,825,200
1,825,200750,0001,125,0000000
       Accounts payable 
1,084,300
0
1,588,434
0
652,400
721,871
1,209,400
1,209,400721,871652,40001,588,43401,084,300
       Other Current Liabilities 
51,800
0
92,145
0
45,900
57,583
103,300
103,30057,58345,900092,145051,800
   > Long-term Liabilities 
0
0
0
0
882,800
774,282
821,200
821,200774,282882,8000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
50,500
42,137
101,600
101,60042,13750,5000000
       Long-term Liabilities Other 
0
0
0
0
392,400
668,400
668,400
668,400668,400392,4000000
> Total Stockholder Equity
0
0
0
0
47,200
312,257
-1,186,800
-1,186,800312,25747,2000000
   Retained Earnings 0-13,705,83800-9,852,94900
   Accumulated Other Comprehensive Income 0000000
   Capital Surplus 0000000
   Treasury Stock0000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue1,372,489
Cost of Revenue-1,266,971
Gross Profit105,518105,518
 
Operating Income (+$)
Gross Profit105,518
Operating Expense-3,333,216
Operating Income-1,960,727-3,227,698
 
Operating Expense (+$)
Research Development-
Selling General Administrative695,227
Selling And Marketing Expenses-
Operating Expense3,333,216695,227
 
Net Interest Income (+$)
Interest Income14,104
Interest Expense-133,287
Net Interest Income-119,183-119,183
 
Pretax Income (+$)
Operating Income-1,960,727
Net Interest Income-119,183
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-2,033,954-1,960,727
EBIT - interestExpense = -133,287
-2,033,954
-1,900,667
Interest Expense133,287
Earnings Before Interest and Taxes (ebit)--1,900,667
Earnings Before Interest and Taxes (ebitda)-1,799,048
 
After tax Income (+$)
Income Before Tax-2,033,954
Tax Provision-0
Net Income From Continuing Ops-2,033,954-2,033,954
Net Income-2,033,954
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-119,183
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NOVC.STU
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of NOVC.STU.

NOVC.STU Daily Candlestick Chart
ZORDIX-B.ST
5 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ZORDIX-B.ST.

ZORDIX-B.ST Daily Candlestick Chart
MRVE3.SA
8 minutes ago

I found you a Death Cross on the daily chart of MRVE3.SA.

MRVE3.SA Daily Candlestick Chart
MOVI3.SA
8 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of MOVI3.SA.

MOVI3.SA Daily Candlestick Chart
LREN3.SA
9 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of LREN3.SA.

LREN3.SA Daily Candlestick Chart
ZENA.OL
9 minutes ago

I found you a Death Cross on the daily chart of ZENA.OL.

ZENA.OL Daily Candlestick Chart
VASCONI.MX
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VASCONI.MX.

VASCONI.MX Daily Candlestick Chart
PUMU.HE
22 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PUMU.HE.

PUMU.HE Daily Candlestick Chart
KTSB.MCX
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of KTSB.MCX.

KTSB.MCX Daily Candlestick Chart
MGNT.MCX
24 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of MGNT.MCX.

MGNT.MCX Daily Candlestick Chart
SIBN.MCX
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SIBN.MCX.

SIBN.MCX Daily Candlestick Chart
FONDIA.HE
26 minutes ago

I found you a Golden Cross on the daily chart of FONDIA.HE.

FONDIA.HE Daily Candlestick Chart
FLXC.SW
27 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FLXC.SW.

FLXC.SW Daily Candlestick Chart
APAM.MC
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of APAM.MC.

APAM.MC Daily Candlestick Chart
PNB.PSE
38 minutes ago

I found you a Golden Cross on the daily chart of PNB.PSE.

PNB.PSE Daily Candlestick Chart
ICT.PSE
39 minutes ago

I found you a Three Black Crows Candle Pattern on the daily chart of ICT.PSE.

ICT.PSE Daily Candlestick Chart
FGEN.PSE
40 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FGEN.PSE.

FGEN.PSE Daily Candlestick Chart
DNL.PSE
40 minutes ago

I found you a Golden Cross on the daily chart of DNL.PSE.

DNL.PSE Daily Candlestick Chart
IDC.PSE
41 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IDC.PSE.

IDC.PSE Daily Candlestick Chart
TGODF.OTCQX
43 minutes ago

I found you a MACD Bearish Hidden Divergence on the daily chart of TGODF.OTCQX.

TGODF.OTCQX Daily Candlestick Chart
SBCB.MCX
44 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of SBCB.MCX.

SBCB.MCX Daily Candlestick Chart
QZM.V
51 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of QZM.V.

QZM.V Daily Candlestick Chart
PFLINFOTC.BSE
1 hour ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of PFLINFOTC.BSE.

PFLINFOTC.BSE Daily Candlestick Chart
XAUUSD.FOREX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XAUUSD.FOREX.

XAUUSD.FOREX Daily Candlestick Chart
USDNZD.FOREX
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of USDNZD.FOREX.

USDNZD.FOREX Daily Candlestick Chart